IDEXX Laboratories Inc. (IDXX) Shows Resilience as Analysts Reassess Targets
IDEXX Laboratories Inc. (NASDAQ:IDXX) is one of the best medical technology stocks to invest in. On February 3, BTIG lowered its price target on IDEXX Laboratories Inc. (NASDAQ:IDXX) to $800 from $830 and maintained a Buy rating. The firm cited concerns about IDEXX’s 2026 guidance despite robust Q4 2025 earnings performance.
IDEXX reported strong fourth-quarter results, with revenue of $1.09 billion, up 14% from last year and above analyst expectations of $1.072 billion. Earnings per share rose 18% to $3.08, beating the Street’s $2.93 estimate. The company remains highly profitable, with a 61.7% gross margin and a return on equity of 65% over the past 12 months.
The companion animal business, IDEXX’s core segment, grew 15% to $998 million, driven by strong instrument revenue of $58 million, up 76% year-over-year. Growth was supported by 1,940 InVueDx system placements, as well as strong demand for Catalyst and SediVue products. This continues IDEXX’s long-term trend of about 10% annual revenue growth and aligns with management’s strategy of share buybacks to boost shareholder value.
For 2026, IDEXX expects revenue of $4.63–$4.72 billion and EPS of $14.29–$14.80, with operating margins slightly improving to 32%–32.5%. BTIG noted a 200-basis-point drag from fewer pet visits, mainly from lower-income owners, but expects 4% price growth globally. The company also plans around 5,500 new InVueDx system placements next year, compared with 6,400 in 2025, to help offset these headwinds.
IDEXX Laboratories Inc. (NASDAQ:IDXX) develops, manufactures, and distributes diagnostic and information technology products for veterinary, livestock, poultry, dairy, and water testing markets. Its offerings include point-of-care diagnostic instruments, rapid assay test kits, veterinary reference laboratory services, and microbiological contaminant testing systems.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Uber Tests Weekend Tokenized Fund Redemptions With HSBC on Canton
Aave Expands Stock-Backed USDC Loans on Base for Eligible Investors
Deciding Next Week’s Market Trend! The Biggest Uncertainty in the US Midterms: Republicans Unexpectedly Hold the Senate vs. Democrats Win Over 53 Seats
Citigroup believes that the expectation of a Democratic sweep of both chambers is largely priced into U.S. stock valuations, with control of the Senate being the key variable. If the Republicans unexpectedly retain the Senate, U.S. stocks may be boosted by year-end; if the Democrats win more than 53 seats, expectations of corporate tax hikes, fiscal negotiations, and regulatory risks for AI data centers will put pressure on the market.
The "Perfect Storm" Script for AI: Bond Market "Sounds the Horn," Earnings Reports "Add Insult to Injury," Will the Election Deliver the "Final Blow"?
The AI boom faces triple threats from the bond market, earnings reports, and political risks: rising financing thresholds have nearly closed the bond market for AI cloud companies; tech giants are increasing capital expenditures and experiencing deteriorating free cash flow, putting pressure on stock prices; with midterm elections approaching, growing opposition to data centers may push for tighter regulations. The market is shifting from pursuing computing power to questioning investment returns.
Crypto prices
More
